#BEGIN_DRUGCARD DB01046

# AHFS_Codes:
Not Available

# ATC_Codes:
A06AX03

# Absorption:
Lubiprostone has low systemic availability following oral administration and concentrations of lubiprostone in plasma are below the level of quantitation (10 pg/mL).

# Biotransformation:
The results of both human and animal studies indicate that lubiprostone is rapidly and extensively metabolized by 15-position reduction, &alpha;-chain &beta;-oxidation, and &omega;-chain &omega;-oxidation. These biotransformations are not mediated by the hepatic cytochrome P450 system but rather appear to be mediated by the ubiquitously expressed carbonyl reductase. M3, a metabolite of lubiprostone in both humans and animals is formed by the reduction of the carbonyl group at the 15-hydroxy moiety that consists of both &alpha;-hydroxy and &beta;-hydroxy epimers. M3 makes up less than 10% of the dose of radiolabeled lubiprostone.

# Brand_Mixtures:
Not Available

# Brand_Names:
Amitiza

# CAS_Registry_Number:
136790-76-6

# ChEBI_ID:
Not Available

# Chemical_Formula:
C20H32F2O5

# Chemical_IUPAC_Name:
7-[(2R,4aR,5S,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-octahydrocyclopenta[b]pyran-5-yl]heptanoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Lubiprostone is a medication used in the management of idiopathic chronic constipation. It is a bicyclic fatty acid (prostaglandin E1 derivative) which acts by specifically activating ClC-2 chloride channels on the apical aspect of gastrointestinal epithelial cells, producing a chloride-rich fluid secretion. These secretions soften the stool, increase motility, and promote spontaneous bowel movements (SBM).

# Dosage_Forms:
Not Available

# Drug_Category:
Anti-constipation Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
17263187	Crowell MD, Harris LA, DiBaise JK, Olden KW: Activation of type-2 chloride channels: a novel therapeutic target for the treatment of chronic constipation. Curr Opin Investig Drugs. 2007 Jan;8(1):66-70.
17519292	Ambizas EM, Ginzburg R: Lubiprostone: a chloride channel activator for treatment of chronic constipation. Ann Pharmacother. 2007 Jun;41(6):957-64. Epub 2007 May 22.
17519292	Ambizas EM, Ginzburg R: Lubiprostone: a chloride channel activator for treatment of chronic constipation. Ann Pharmacother. 2007 Jun;41(6):957-64. Epub 2007 May 22.
18686757	Lacy BE, Levy LC: Lubiprostone: a novel treatment for chronic constipation. Clin Interv Aging. 2008;3(2):357-64.
19236188	Lacy BE, Chey WD: Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. Expert Opin Pharmacother. 2009 Jan;10(1):143-52.

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
4.3

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Practically insoluble

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Lubiprostone

# HET_ID:
Not Available

# Half_Life:
0.9 to 1.4 hours

# InChI_Identifier:
InChI=1S/C20H32F2O5/c1-2-3-11-19(21,22)20(26)12-10-15-14(16(23)13-17(15)27-20)8-6-4-5-7-9-18(24)25/h14-15,17,26H,2-13H2,1H3,(H,24,25)/t14-,15+,17+,20+/m0/s1

# InChI_Key:
InChIKey=WGFOBBZOWHGYQH-DKYLXPRQSA-N

# Indication:
For the treatment of chronic idiopathic constipation in the adult population. Also used for the treatment of irritable bowel syndrome with constipation in women who are 18 years of age or older.

# KEGG_Compound_ID:
C13707

# KEGG_Drug_ID:
D04790

# LIMS_Drug_ID:
1046

# Mechanism_Of_Action:
Lubiprostone acts by specifically activating ClC-2 chloride channels, which is a normal constituent of the apical membrane of the human intestine, in a protein kinase A action independent fashion. Activation of ClC-2 chloride channels causes an efflux of chloride ions into the lumen, which in turn leads to an efflux of sodium ions through a paracellular pathway to maintain isoelectric neutrality. As a result, water follows sodium into the lumen in order to maintain isotonic equilibrium, thereby increasing intestinal fluid secretion. By increasing intestinal fluid secretion, lubiprostone increases motility in the intestine, thereby increasing the passage of stool and alleviating symptoms associated with chronic idiopathic constipation. Activation of ClC-2 chloride channels may also stimulate the recovery of muscosal barrier function by restoring tight junction protein complexes in the intestine. Patch clamp cell studies in human cell lines have indicated that the majority of the beneficial biological activity of lubiprostone and its metabolites is observed only on the apical (luminal) portion of the gastrointestinal epithelium.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
390.4619

# Molecular_Weight_Mono:
390.221780544

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164777012

# Pharmacology:
Chronic idiopathic constipation is generally defined by infrequent or difficult passage of stool. The signs and symptoms associated with chronic idiopathic constipation (i.e., abdominal pain or discomfort, bloating, straining, and hard or lumpy stools) may be the result of abnormal colonic motility that can delay the transit of intestinal contents and impede the evacuation of rectal contents. One approach to the treatment of chronic idiopathic constipation is the secretion of fluid into the abdominal lumen through the activation of chloride channels in the apical membrane of the gastrointestinal epithelium. Lubiprostone is a locally acting chloride channel activator that increases intestinal chloride and fluid secretion without altering sodium and potassium concentrations in the serum.

# Predicted_LogP_Hydrophobicity:
2.76

# Predicted_LogS:
-4.2

# Predicted_Water_Solubility:
2.56e-02 g/l

# Primary_Accession_No:
DB01046

# Protein_Binding:
94%

# PubChem_Compound_ID:
656719

# PubChem_Substance_ID:
46505874

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD01298

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@@]12CC(=O)[C@@H](CCCCCCC(O)=O)[C@@]1([H])CC[C@@](O)(O2)C(F)(F)CCCC

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
RU-0211

# Synthesis_Reference:
Not Available

# Toxicity:
In a definitive Phase 1 cardiac repolarization study, 51 patients were administered a single oral dose of 144 mcg of lubiprostone, which is 6 times the normal single administration dose. Thirty-nine (39) of the 51 patients experienced an adverse event. The adverse events reported in >1% of this group included the following: nausea (45.1%), vomiting (27.5%), diarrhea (25.5%), dizziness (17.6%), loose or watery stools (13.7%), headache (11.8%), retching (7.8%), abdominal pain (5.9%), flushing or hot flush (5.9%), dyspnea (3.9%), pallor (3.9%), stomach discomfort (3.9%), syncope (3.9%), upper abdominal pain (2.0%), anorexia (2.0%), asthenia (2.0%), chest discomfort (2.0%), dry mouth (2.0%), hyperhidrosis (2.0%), skin irritation (2.0%) and vasovagal episode (2.0%).

# Update_Date:
2013-02-08 16:19:51 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Lubiprostone

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CBR1

# Phase_1_Metabolizing_Enzyme_1_ID:
5251

# Phase_1_Metabolizing_Enzyme_1_Name:
Carbonyl reductase [NADPH] 1

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Carbonyl reductase [NADPH] 1
MSSGIHVALVTGGNKGIGLAIVRDLCRLFSGDVVLTARDVTRGQAAVQQLQAEGLSPRFH
QLDIDDLQSIRALRDFLRKEYGGLDVLVNNAGIAFKVADPTPFHIQAEVTMKTNFFGTRD
VCTELLPLIKPQGRVVNVSSIMSVRALKSCSPELQQKFRSETITEEELVGLMNKFVEDTK
KGVHQKEGWPSSAYGVTKIGVTVLSRIHARKLSEQRKGDKILLNACCPGWVRTDMAGPKA
TKSPEEGAETPVYLALLPPDAEGPHGQFVSEKRVEQW

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P16152

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
15991886	Lubiprostone: RU 0211, SPI 0211. Drugs R D. 2005;6(4):245-8.
17053162	Moeser AJ, Nighot PK, Engelke KJ, Ueno R, Blikslager AT: Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone. Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G647-56. Epub 2006 Oct 19.
17263187	Crowell MD, Harris LA, DiBaise JK, Olden KW: Activation of type-2 chloride channels: a novel therapeutic target for the treatment of chronic constipation. Curr Opin Investig Drugs. 2007 Jan;8(1):66-70.
17413599	Lacy BE, Campbell Levy L: Lubiprostone: a chloride channel activator. J Clin Gastroenterol. 2007 Apr;41(4):345-51.
17509103	Johanson JF, Ueno R: Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther. 2007 Jun 1;25(11):1351-61.
17519292	Ambizas EM, Ginzburg R: Lubiprostone: a chloride channel activator for treatment of chronic constipation. Ann Pharmacother. 2007 Jun;41(6):957-64. Epub 2007 May 22.
18686757	Lacy BE, Levy LC: Lubiprostone: a novel treatment for chronic constipation. Clin Interv Aging. 2008;3(2):357-64.
19236188	Lacy BE, Chey WD: Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. Expert Opin Pharmacother. 2009 Jan;10(1):143-52.
20345211	Kapoor S: Emerging new therapeutic options for the management of opioid induced constipation. J Pain Palliat Care Pharmacother. 2010 Mar;24(1):98-9.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
CLCN2

# Drug_Target_1_GenBank_ID_Gene:
AF026004

# Drug_Target_1_GenBank_ID_Protein:
2570864

# Drug_Target_1_GeneCard_ID:
CLCN2

# Drug_Target_1_Gene_Name:
CLCN2

# Drug_Target_1_Gene_Sequence:
>2697 bp
ATGGCGGCCGCGGCGGCGGAGGAAGGGATGGAGCCACGGGCGCTGCAGCACGAGCAGACC
CTGATGTATGGCCGGTACACTCAGGACCTTGGGGCCTTTGCCAAAGAGGAAGCTGCTCGG
ATTCGCCTGGGAGGGCCTGAACCCTGGAAAGGTCCCCCTTCCTCTCGGGCTGCCCCAGAG
CTCTTGGAATATGGACGGAGCCGTTGCGCCCGATGCCGCGTCTGTTCTGTCCGCTGCCAC
AAGTTCCTAGTATCCAGGGTTGGTGAAGATTGGATCTTCCTGGTCCTGCTGGGGCTTCTC
ATGGCATTGGTCAGCTGGGTCATGGACTATGCCATTGCTGCCTGTCTGCAAGCCCAGCAG
TGGATGTCCCGGGGCTTGAACACCAGCATCTTGCTCCAGTACCTGGCCTGGGTCACCTAC
CCTGTTGTCCTCATCACTTTCTCAGCCGGATTCACACAGATCCTGGCCCCTCAGGCTGTC
GGCTCTGGCATCCCTGAGATGAAGACCATCTTGCGGGGAGTGGTGCTGAAAGAATACCTC
ACACTCAAGACCTTTATAGCTAAGGTCATTGGGCTGACCTGCGCCCTAGGCAGCGGGATG
CCGCTTGGCAAAGAGGGCCCTTTTGTGCATATCGCAAGCATGTGTGCTGCCCTTCTCAGC
AAGTTCCTCTCCCTCTTTGGGGGTATCTATGAGAATGAATCCCGGAACACAGAGATGCTG
GCTGCCGCCTGTGCCGTGGGGGTGGGCTGCTGCTTCGCGGCACCTATTGGAGGCGTCCTC
TTCAGCATCGAGGTCACCTCCACCTTCTTTGCAGTGCGGAACTACTGGCGGGGCTTCTTC
GCTGCCACCTTCAGTGCCTTCATCTTCCGGGTCTTGGCAGTCTGGAACCGGGATGAAGAG
ACTATTACAGCCCTCTTCAAAACCCGATTCCGGCTCGACTTCCCCTTTGACCTGCAGGAG
CTGCCAGCCTTTGCTGTCATTGGTATTGCTAGTGGCTTCGGTGGAGCCCTCTTTGTCTAC
CTGAACCGGAAGATTGTCCAGGTGATGCGGAAGCAGAAAACCATCAATCGCTTCCTCATG
AGGAAACGCCTGCTCTTCCCGGCTCTGGTGACCCTGCTCATCTCCACGCTGACCTTCCCC
CCTGGCTTTGGACAGTTCATGGCTGGACAGCTCTCACAGAAAGAGACGCTGGTCACCCTG
TTTGACAATCGGACGTGGGTCCGCCAGGGCCTGGTGGAGGAGCTAGAACCACCCAGCACC
TCACAGGCCTGGAACCCACCACGTGCCAACGTCTTCCTCACCCTGGTCATCTTCATTCTC
ATGAAGTTCTGGATGTCTGCACTGGCCACCACCATCCCAGTTCCCTGTGGGGCCTTCATG
CCTGTCTTTGTCATTGGAGCAGCATTTGGGCGTCTGGTGGGTGAAAGCATGGCTGCCTGG
TTCCCAGATGGAATTCATACGGACAGCAGCACCTACCGGATTGTGCCTGGGGGCTACGCT
GTGGTCGGGGCAGCTGCGCTGGCAGGAGCGGTGACACACACAGTGTCCACGGCTGTGATC
GTGTTCGAGCTCACAGGCCAGATTGCCCACATCCTGCCTGTCATGATCGCCGTCATCCTG
GCCAACGCTGTCGCCCAGAGTCTGCAGCCCTCCCTCTATGACAGCATCATCCGAATCAAG
AAACTGCCCTACCTGCCTGAGCTCGGCTGGGGCCGCCACCAGCAGTACCGGGTGCGTGTG
GAGGACATCATGGTGCGGGATGTTCCCCATGTGGCCCTCAGCTGCACCTTCCGGGACCTG
CGTTTGGCACTGCACAGGACCAAGGGCCGAATGCTGGCCCTAGTGGAGTCCCCTGAGTCC
ATGATTCTGCTGGGCTCCATCGAGCGTTCACAGGTGGTGGCATTGTTGGGGGCCCAGCTG
AGCCCAGCCCGCCGGCGGCAGCACATGCAGGAGCGCAGAGCCACCCAGACCTCTCCACTA
TCTGATCAGGAGGGTCCCCCTAGCCCTGAGGCTTCTGTCTGCTTCCAGGTGAACACAGAA
GACTCAGCCTTCCCAGCAGCCCGGGGGGAGACCCACAAGCCCCTAAAGCCTGCACTCAAG
AGGGGGCCCAGTGTCACCAGGAACCTCGGAGAGAGTCCCACAGGGAGCGCAGAGTCGGCA
GGCATCGCCCTCCGGAGCCTCTTCTGTGGCAGTCCACCCCCTGAGGCTGCTTCGGAGAAG
TTGGAATCCTGTGAGAAGCGCAAGCTGAAGCGTGTCCGAATCTCCCTGGCAAGTGACGCG
GACCTGGAAGGCGAGATGAGCCCTGAAGAGATTCTGGAGTGGGAGGAGCAGCAACTAGAT
GAACCTGTCAACTTCAGTGACTGCAAAATTGATCCTGCTCCCTTCCAGCTGGTGGAGCGG
ACCTCTTTGCACAAGACTCACACTATCTTCTCACTGCTGGGAGTGGACCATGCTTATGTC
ACCAGTATTGGCAGACTCATTGGAATCGTTACTCTAAAGGAGCTCCGGAAGGCCATCGAG
GGCTCTGTCACAGCACAGGGTGTGAAAGTCCGGCCGCCCCTCGCCAGCTTCCGAGACAGT
GCCACCAGCAGCAGTGACACGGAGACCACTGAGGTGCATGCACTCTGGGGGCCCCACTCC
CGTCATGGCCTCCCCCGGGAGGGCAGCCCTTCCGACAGCGACGACAAATGCCAATGA

# Drug_Target_1_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_1_General_References:
10198195	Lamb FS, Clayton GH, Liu BX, Smith RL, Barna TJ, Schutte BC: Expression of CLCN voltage-gated chloride channel genes in human blood vessels. J Mol Cell Cardiol. 1999 Mar;31(3):657-66.
12612585	Haug K, Warnstedt M, Alekov AK, Sander T, Ramirez A, Poser B, Maljevic S, Hebeisen S, Kubisch C, Rebstock J, Horvath S, Hallmann K, Dullinger JS, Rau B, Haverkamp F, Beyenburg S, Schulz H, Janz D, Giese B, Muller-Newen G, Propping P, Elger CE, Fahlke C, Lerche H, Heils A: Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies. Nat Genet. 2003 Apr;33(4):527-32. Epub 2003 Mar 3.
7795595	Cid LP, Montrose-Rafizadeh C, Smith DI, Guggino WB, Cutting GR: Cloning of a putative human voltage-gated chloride channel (CIC-2) cDNA widely expressed in human tissues. Hum Mol Genet. 1995 Mar;4(3):407-13.

# Drug_Target_1_HGNC_ID:
HGNC:2020

# Drug_Target_1_HPRD_ID:
02782

# Drug_Target_1_ID:
842

# Drug_Target_1_Locus:
3q27-q28

# Drug_Target_1_Molecular_Weight:
98497

# Drug_Target_1_Name:
Chloride channel protein 2

# Drug_Target_1_Number_of_Residues:
898

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00571	CBS
PF00654	Voltage_CLC

# Drug_Target_1_Protein_Sequence:
>Chloride channel protein 2
MAAAAAEEGMEPRALQHEQTLMYGRYTQDLGAFAKEEAARIRLGGPEPWKGPPSSRAAPE
LLEYGRSRCARCRVCSVRCHKFLVSRVGEDWIFLVLLGLLMALVSWVMDYAIAACLQAQQ
WMSRGLNTSILLQYLAWVTYPVVLITFSAGFTQILAPQAVGSGIPEMKTILRGVVLKEYL
TLKTFIAKVIGLTCALGSGMPLGKEGPFVHIASMCAALLSKFLSLFGGIYENESRNTEML
AAACAVGVGCCFAAPIGGVLFSIEVTSTFFAVRNYWRGFFAATFSAFIFRVLAVWNRDEE
TITALFKTRFRLDFPFDLQELPAFAVIGIASGFGGALFVYLNRKIVQVMRKQKTINRFLM
RKRLLFPALVTLLISTLTFPPGFGQFMAGQLSQKETLVTLFDNRTWVRQGLVEELEPPST
SQAWNPPRANVFLTLVIFILMKFWMSALATTIPVPCGAFMPVFVIGAAFGRLVGESMAAW
FPDGIHTDSSTYRIVPGGYAVVGAAALAGAVTHTVSTAVIVFELTGQIAHILPVMIAVIL
ANAVAQSLQPSLYDSIIRIKKLPYLPELGWGRHQQYRVRVEDIMVRDVPHVALSCTFRDL
RLALHRTKGRMLALVESPESMILLGSIERSQVVALLGAQLSPARRRQHMQERRATQTSPL
SDQEGPPSPEASVCFQVNTEDSAFPAARGETHKPLKPALKRGPSVTRNLGESPTGSAESA
GIALRSLFCGSPPPEAASEKLESCEKRKLKRVRISLASDADLEGEMSPEEILEWEEQQLD
EPVNFSDCKIDPAPFQLVERTSLHKTHTIFSLLGVDHAYVTSIGRLIGIVTLKELRKAIE
GSVTAQGVKVRPPLASFRDSATSSSDTETTEVHALWGPHSRHGLPREGSPSDSDDKCQ

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Voltage-gated chloride channel. Chloride channels have several functions including the regulation of cell volume; membrane potential stabilization, signal transduction and transepithelial transport

# Drug_Target_1_SwissProt_ID:
P51788

# Drug_Target_1_SwissProt_Name:
CLCN2_HUMAN

# Drug_Target_1_Synonyms:
ClC-2

# Drug_Target_1_Theoretical_pI:
8.47

# Drug_Target_1_Transmembrane_Regions:
91-110
132-155
179-200
208-227
239-263
278-296
321-341
364-387
431-450
453-471
499-520
528-547
808-826

#END_DRUGCARD DB01046
